Determination of mutations in iron regulating genes of beta thalassemia major patients of Khyber Pakhtunkhwa, Pakistan.
HAMP
HFE
G71D
H63D
Hemochromatosis
Hepcidin
beta thalassemia major
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
30
01
2020
revised:
20
04
2020
accepted:
28
04
2020
pubmed:
27
6
2020
medline:
21
5
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
Hepcidin and hemochromatosis (HFE) are iron regulatory proteins that are encoded by HAMP and HFE genes. Mutation in either HAMP gene or HFE gene causes Hepcidin protein deficiency that can lead to iron overload in beta thalassemia patients. The aim of this research work was to study the presence of G71D mutation of HAMP gene and H63D mutation of HFE gene in beta thalassemia major and minor group to check the association of these mutations with serum ferritin level of beta thalassemia patients. The study was conducted on 42 beta thalassemia major and 20 beta thalassemia minor samples along with 20 control samples. The genotyping of both mutations has done by ARM-PCR technique with specific set of primers. Significant effect of G71D and H63D mutations was observed on serum ferritin level of thalassemia major group. The risk allele of HAMP G71D and HFE H63D was found with high frequency (48% and 49%, respectively) in beta thalassemia major than in control group. High genotypic frequency of HAMP and HFE gene mutation gene mutation was observed in beta thalassemia major than beta thalassemia minor and control group (7% and 9%, respectively). It can be concluded that both HAMP and HFE gene mutations show high frequency in beta thalassemia major patients and mean significant association between mutations and high serum ferritin level of beta thalassemia major patients but the nonsignificant results of Odd ratios showed that both mutations do not act as major risk factor in beta thalassemia major.
Sections du résumé
BACKGROUND
Hepcidin and hemochromatosis (HFE) are iron regulatory proteins that are encoded by HAMP and HFE genes. Mutation in either HAMP gene or HFE gene causes Hepcidin protein deficiency that can lead to iron overload in beta thalassemia patients. The aim of this research work was to study the presence of G71D mutation of HAMP gene and H63D mutation of HFE gene in beta thalassemia major and minor group to check the association of these mutations with serum ferritin level of beta thalassemia patients.
METHODS
The study was conducted on 42 beta thalassemia major and 20 beta thalassemia minor samples along with 20 control samples. The genotyping of both mutations has done by ARM-PCR technique with specific set of primers.
RESULTS
Significant effect of G71D and H63D mutations was observed on serum ferritin level of thalassemia major group. The risk allele of HAMP G71D and HFE H63D was found with high frequency (48% and 49%, respectively) in beta thalassemia major than in control group. High genotypic frequency of HAMP and HFE gene mutation gene mutation was observed in beta thalassemia major than beta thalassemia minor and control group (7% and 9%, respectively).
CONCLUSION
It can be concluded that both HAMP and HFE gene mutations show high frequency in beta thalassemia major patients and mean significant association between mutations and high serum ferritin level of beta thalassemia major patients but the nonsignificant results of Odd ratios showed that both mutations do not act as major risk factor in beta thalassemia major.
Identifiants
pubmed: 32588561
doi: 10.1002/mgg3.1310
pmc: PMC7507326
doi:
Substances chimiques
HAMP protein, human
0
HFE protein, human
0
Hemochromatosis Protein
0
Hepcidins
0
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1310Informations de copyright
© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
Ann N Y Acad Sci. 2010 Aug;1202:31-5
pubmed: 20712769
J Biol Chem. 2001 Mar 16;276(11):7811-9
pubmed: 11113132
Blood. 2006 Dec 1;108(12):3730-5
pubmed: 16882706
Can J Gastroenterol. 2009 Dec;23(12):822-8
pubmed: 20011735
J Clin Invest. 2002 Oct;110(7):1037-44
pubmed: 12370282
Mol Genet Genomic Med. 2020 Sep;8(9):e1310
pubmed: 32588561
Acta Haematol. 2007;118(2):99-105
pubmed: 17637512
Proc (Bayl Univ Med Cent). 2007 Jan;20(1):27-31
pubmed: 17256039
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):338-43
pubmed: 15528154
J Nutr. 2002 Dec;132(12):3680-6
pubmed: 12468607
Blood. 2003 Apr 1;101(7):2461-3
pubmed: 12433676
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1472-7
pubmed: 9465039
Ann N Y Acad Sci. 2010 Aug;1202:221-5
pubmed: 20712796
Haematologica. 2002 Mar;87(3):242-5
pubmed: 11869934
Eur J Haematol. 2007 Jan;78(1):66-71
pubmed: 17042772
Orphanet J Rare Dis. 2010 May 21;5:11
pubmed: 20492708
Cardiovasc Hematol Agents Med Chem. 2012 Mar 1;10(1):25-30
pubmed: 22239492
Indian J Hematol Blood Transfus. 2014 Dec;30(4):281-5
pubmed: 25435728
Best Pract Res Clin Haematol. 2002 Jun;15(2):329-68
pubmed: 12401311
Blood. 2004 Apr 1;103(7):2835-40
pubmed: 14670915
Adv Hematol. 2010;2010:938640
pubmed: 20508726
Blood. 2006 Nov 1;108(9):3204-9
pubmed: 16835372
Biochim Biophys Acta. 2009 Jul;1790(7):694-701
pubmed: 18992790
Genet Med. 2010 Feb;12(2):61-76
pubmed: 20098328
Acta Haematol. 2009;122(2-3):78-86
pubmed: 19907144
Nephrol Dial Transplant. 2014 Jun;29(6):1141-4
pubmed: 24286977
Maedica (Bucur). 2013 Sep;8(4):328-32
pubmed: 24790662
Br J Haematol. 2013 Mar;160(5):680-7
pubmed: 23278768
Chin Med J (Engl). 2017 Apr 5;130(7):866-871
pubmed: 28345552
Haematologica. 2006 Mar;91(3):ELT02
pubmed: 16533735
Eur J Hum Genet. 2005 Nov;13(11):1172-85
pubmed: 16132052
Br J Haematol. 2000 Dec;111(3):908-14
pubmed: 11122155
Clin Ther. 2007 May;29(5):909-917
pubmed: 17697909
Science. 2004 Dec 17;306(5704):2090-3
pubmed: 15514116
Hum Mol Genet. 2003 Sep 1;12(17):2241-7
pubmed: 12915468
Ann Hematol. 2009 Oct;88(10):951-5
pubmed: 19214511